These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10884803)

  • 1. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
    Abramovich CM; Prayson RA
    Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of apoptotic and proliferation markers in meningiomas.
    Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
    J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of cathepsin D in meningiomas.
    Castilla EA; Prayson RA; Abramovich CM; Cohen ML
    Am J Clin Pathol; 2003 Jan; 119(1):123-8. PubMed ID: 12520707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery for convexity meningiomas.
    Morokoff AP; Zauberman J; Black PM
    Neurosurgery; 2008 Sep; 63(3):427-33; discussion 433-4. PubMed ID: 18812953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
    Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
    Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
    Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM
    Cancer; 1998 Jun; 82(11):2262-9. PubMed ID: 9610708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
    Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
    No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
    Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
    Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCNA, Ki-67 and hTERT in residual benign meningiomas.
    Maes L; Kalala JP; Cornelissen M; De Ridder L
    In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence and regrowth of benign meningiomas.
    Nakasu S; Fukami T; Jito J; Nozaki K
    Brain Tumor Pathol; 2009; 26(2):69-72. PubMed ID: 19856217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspase-3 immunohistochemical expression is a marker of apoptosis, increased grade and early recurrence in intracranial meningiomas.
    Konstantinidou AE; Givalos N; Gakiopoulou H; Korkolopoulou P; Kotsiakis X; Boviatsis E; Agrogiannis G; Mahera H; Patsouris E
    Apoptosis; 2007 Apr; 12(4):695-705. PubMed ID: 17143787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas.
    Takei H; Buckleair LW; Powell SZ
    Neuropathology; 2008 Feb; 28(1):62-8. PubMed ID: 18021195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.